يعرض 541 - 560 نتائج من 19,593 نتيجة بحث عن '(( significant increase decrease ) OR ( significantly ((a decrease) OR (larger decrease)) ))', وقت الاستعلام: 0.80s تنقيح النتائج
  1. 541
  2. 542
  3. 543
  4. 544
  5. 545
  6. 546

    The strength of the commute time-functional connectivity relationship demonstrates weak pathological significance and weak dependency on age. حسب Rostam M. Razban (22232522)

    منشور في 2025
    "…The corresponding Kolmogorov-Smirnov pairwise tests are not significant (S5 Table in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0331085#pone.0331085.s001" target="_blank">SI</a>). …"
  7. 547
  8. 548
  9. 549
  10. 550
  11. 551

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  12. 552

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  13. 553

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  14. 554
  15. 555
  16. 556
  17. 557
  18. 558
  19. 559
  20. 560

    A representative ultrasound axis image. حسب Eun-Seon Yang (19751340)

    منشور في 2024
    الموضوعات: